Oleg from Hong Kong

Registered at the short selling broker Kriptomat, 5 minutes ago.

» Try Kriptomat you too
Don't show again

Novartis AG (NVS) shares information

Novartis AG – ADR

24h Change

-0.93 %


Live rate: Market closed

Stock data per Friday 22 Sep, 2023

-0.95 (-0.93%)
US Market is closed

Live Stock price in graph for Novartis AG – ADR (NVS)

  • Latest Volume

    792,852 (-24.69 %)

  • Volume prev. day


  • Avg. daily volume


  • Market cap


  • P/E ratio


  • Today high

    101.77 USD

  • Today low

    101.03 USD

  • 52 week high

    105.61 USD

  • 52 week low

    71 USD

  • YTD Change

    + 15.40 %

Quick links


Latest news about Novartis AG – ADR

Below you can find the most recent news posts about Novartis AG – ADR, primarily from US and UK based news sources.

Prothena: Switching From ”Hold” To ”Buy” On Lead Alzheimer”s Drug Promise

Thursday, 21 September 2023, 19:39:18
Prothena has lucrative development partnerships with Roche, Novartis, and Bristol Myers Squibb. Click here to see why I am upgrading PRTA stock from Hold to Buy.
— Seeking Alpha

Novartis: fin de l”accord de collaboration avec BeiGene

Wednesday, 20 September 2023, 16:09:00
(CercleFinance.com) – Novartis et BeiGene ont convenu de mettre fin à leur accord de collaboration et de licence pour le tislelizumab, un anticorps monoclonal IgG4 humanisé anti-PD-1 – 20/09/2023 à 16:09 – Boursorama
— Boursorama

Novartis cancels Beigene partnership as cancer drug gains EU approval

Tuesday, 19 September 2023, 23:39:13
… -treat cancers like melanoma and lung cancer , which could make it tough … BeiGene has sole rights, in lung cancer , lymphoma and other indications. Novartis … project recently showed promise in lung cancer . Following news of the deal …
— EIN News Lung Cancer

Chinese Drugmaker BeiGene And Novartis Move Out From Second Cancer Drug Pact

Tuesday, 19 September 2023, 15:18:52
BeiGene Ltd (NASDAQ: BGNE ) said it would regain rights to develop, manufacture, and commercialize Tevimbra (tislelizumab), its cancer drug, from Novartis AG (NYSE: NVS ). Under the agreement signed in 2021, the companies were jointly developing the drug tislelizumab. BeiGene has launched more than 20 potentially registration-enabling trials with Tevimbra, of which 10 Phase 3 trials and four Phase 2 trials have a lready had positive readouts . Minutes later, BeiGene said … Full story available on Benzinga.com
— Benzinga

BeiGene Strengthens Global Portfolio and Regains Full Rights from Novartis for Anti-PD-1 Antibody TEVIMBRA® (tislelizumab) | BGNE Stock News

Tuesday, 19 September 2023, 13:00:00
Regulatory marketing applications for U.S. and EU under review, with plans to expand TEVIMBRA commercial presence worldwide.
— Stock Titan

Trading broker recommendation

We recommend that you check out Capital.com as they have a very good selection of stocks available for both going short and long.

Rating: 9.57/10
Minimum deposit: €250 by bank
Description: Capital.com offer a large number of stocks for trading. Register an account today and check if they have NVS available or trade one of the many other CFD stocks they have.
Risk warning: 67.7% of retail investor accounts lose money when trading CFDs with Capital.